U.S. markets closed

Zogenix, Inc. (ZGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.20+0.28 (+1.56%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close17.92
Bid17.38 x 800
Ask18.50 x 1000
Day's Range17.68 - 18.31
52 Week Range16.73 - 32.42
Avg. Volume681,746
Market Cap1.016B
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-4.30
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zogenix, Inc. (NASDAQ:ZGNX) Insiders Increased Their Holdings
    Simply Wall St.

    Zogenix, Inc. (NASDAQ:ZGNX) Insiders Increased Their Holdings

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

  • Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

    Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

    EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a virtual fireside chat on Thursday, May 13, 2021, at the BofA Securities 2021 Healthcare Conference. Zogenix Presentation DetailsDate:Thursday, May 13, 2021Time:3:30 PM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies. CONTACTS: ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 | corpcomms@zogenix.com InvestorsBrian Ritchie Managing Director, LifeSci Advisors LLC+1 (212) 915-2578 | britchie@lifesciadvisors.com MediaStefanie Tuck, Vice President, Porter Novelli+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

  • Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates

    Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates

    Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?